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Aims We wish to assess the clinical and cost-effectiveness of remote monitoring of heart failure patients with cardiac
implanted electronic devices.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods REM-HF is a multicentre, randomized, non-blinded, parallel trial designed to compare weekly remote
monitoring-driven management with usual care for patients with cardiac implanted electronic devices (ICD,
CRT-D, or CRT-P). The trial is event driven, and the final analysis will be performed when 546 events have been
observed or the study is terminated at the interim analysis. We have randomized 1650 patients to be followed up
for a minimum of 2 years. Patients will remain in the trial up to study termination. The first patient was randomized
in September 2011 and the study is expected to complete in early 2016. The primary combined endpoint is time to
first event of all-cause death or unplanned hospitalization for cardiovascular reasons. An economic evaluation will
be performed, estimating the cost per quality-adjusted lifeyear, with direct costs estimated from the National Health
Service perspective and quality of life assessed by the EQ-5D, Short-Form12, and Kansas City Cardiomyopathy
Questionnaires. The study design has been informed by a feasibility study.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion REM-HF is a multicentre randomized study that will provide important data on the effect of remote monitoring-driven
management of implanted cardiac devices on morbidity and mortality, as well as the cost-effectiveness of this
approach.
Trial registration: UKCRN 10383.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
Up to 2–3% of the population have chronic heart failure (HF).1
A recent study in England reported that one-third of people
with HF have dyspnoea that severely limits physical activity,2 and
quality of life is poor relative to patients with other chronic
conditions.3 Approximately 2% of healthcare budgets in most
developed countries are spent on HF management, with >60% of
this related to the costs of hospitalization.4 The UK National HF
Audit most recently reported data from 92% of hospitals, with a
mean duration of hospitalization of 13.1 days, and a death rate of
30% at 1 year.5 Reduction in HF admissions is therefore key to
reducing the overall cost of HF to the healthcare system.
An increasing proportion of patients with chronic HF have
implanted electronic cardiac devices, such as an implantable car-
dioverter defibrillator (ICD) or cardiac resynchronization therapy
(CRT-P), or a combination of both (CRT-D). Such devices can
collect information not only on device function and activity, but
also on various physiological characteristics, including patient activ-
ity, transthoracic impedance, heart rate variability, nocturnal heart
rate, and arrhythmia burden.6 In England, the current implant rate
for such devices is ∼100–130 per million population.7
Investigators have considered the use of non-invasive monitor-
ing technologies for remote HF management.8,9 Moreover, several
small studies have assessed the impact of remote monitoring of
one or more physiological variables from implanted devices on
patient and healthcare outcomes. Bourge et al. evaluated a remote
monitoring strategy for 274 patients with HF using right ventric-
ular haemodynamic data.10 There was a non-significant reduction
of 21% in HF-related events in those randomized to remote
monitoring, with a significant 36% (P = 0.03) reduction in the
secondary endpoint of HF-related hospitalization. More recently,
the CHAMPION trial reported a 30% drop in the 6-month risk of
HF hospitalization using remote monitoring of pulmonary artery
pressure measured by an implantable sensor.11
Yu and colleagues retrospectively evaluated an implantable sys-
tem capable of intrathoracic impedance monitoring in 33 patients
with advanced HF.12 Using an automated detection algorithm, an
impedance drop below a threshold value was 77% sensitive in
detecting hospitalization for fluid overload, with 1.5 false-positive
(threshold crossing without hospitalization) detections per
patient-year of follow-up. A larger observational study in 501
patients (SENSE-HF) reported a sensitivity of only 21% and a higher
false-positive rate,13 and a randomized controlled trial (DOT-HF)
was stopped early due to slow recruitment after 335 patients
were randomized, and reported a 79% increase (P = 0.02) in HF
hospitalizations when the patient and the physician were ‘alerted’
to the crossing of a threshold of intrathoracic impedance.14
Retrospectively examining the clinical utility of a combination
of physiological variables measured by implanted devices has
suggested greater benefit from synthesizing information (and
trends over time) from several variables rather than just relying
on one variable. PARTNERS-HF reported that such use of data
was able to stratify patients into low, medium, and high risk for
decompensation (requiring hospitalization) in the next month.6
More recently, Cowie and colleagues reported even better results ..
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.. from combining a larger number of data sets: monthly diagnostic
evaluations in the high-risk group were 10 times more likely
to have a HF hospitalization (event rate 6.8%) in the next 30
days compared with monthly evaluations in the low-risk group
(event rate 0.6%).15 Neither study prospectively tested whether
such data could be used by healthcare professionals to reduce
hospitalization safely and improve outcome.
The RAPID-RF (Remote Active Monitoring in Patients with
Heart Failure) Registry is enrolling up to 1000 patients at 100
centres to evaluate the effect of ‘alerts’ from an implanted device,
in combination with data on weight and symptoms collected from a
linked external device.16 Preliminary data suggest that the majority
of alerts relate to weight rather than device-related information,
and the predictive value has not been assessed. It uses only one
manufacturer’s technology and did not employ specific remote
monitoring care pathways.
Recently, 716 HF patients in Germany with an implantable
cardiac device were randomized to either home monitoring or
usual care (IN-TIME Study). At 12 months, fewer patients had
worsened HF in the remote monitoring group (19% vs. 28%; P <
0.05), and the mortality was also lower (3.4% vs. 8.7%, P = 0.012).
Remote monitoring using stand-alone technologies (external to
the body) have also been examined in a number of randomized
trials. Many of these trials were small, and although a recent
Cochrane review17 suggested benefit in terms of all-cause mortality
and HF hospitalization, a more recent network meta-analysis
did not confirm this.18 Two recent large randomized trials have
been neutral.19,20 One large study in England, involving 3230
patients with diabetes, chronic lung disease, or HF, reported
clinically important reductions in hospitalizations, emergency room
admissions, and mortality,21 but at a cost considered prohibitive at
>£90 000 (€105 000) per quality-adjusted life year (QALY) when
added to usual care.22
Prospective randomized studies of remote monitoring of HF
patients using implantable devices have not been of adequate size
or duration to assess the clinical and cost-effectiveness of such
an approach robustly in a general healthcare setting. The REM-HF
(REmote Monitoring: an evaluation of implantable devices for
management of Heart Failure patients) Study has been designed to
address these issues, and is based on personalized care informed
by remote monitoring of patient activity, arrhythmia burden, and
potential signs of decompensation from implanted devices, using
specifically trained remote monitoring staff working to pilot-tested
guidelines. The remote monitoring staff interact closely with the
clinical teams caring for the patients at the nine hospitals in England
which will recruit to the study.
Study design
The feasibility study
A feasibility study was used to plan the REM-HF study: 80 HF
patients in two cohorts were recruited from one tertiary care
centre (Southampton, UK). Patients had ICDs or CRT-Ds. Patients
recruited to the feasibility study were stable, on optimal tolerated
medical therapy for at least 6 weeks prior to recruitment, and had
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Table 1 Clinical features of those patients enrolled in
the two cohorts of the feasibility study for REM-HF
Cohort 1
(n = 40)
Cohort 2
(n = 40)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Average age (years)
(mean ± SD)
70.7 ± 7. 7 70.4 ± 7.2 0.82
Male (n, %) 36 (90%) 38 (95%) 0.40
Ischaemic aetiology
(n, %)
19 (48%) 22 (55%) 0.50
Previous CABG (n, %) 16 (40%) 17 (42%) 0.82
Previous PCI (n, %) 6 (15%) 6 (15%) 1.0
Previous MI (n, %) 24 (60%) 28 (70%) 0.35
Angina (n, %) 13 (33%) 14 (35%) 0.81
Diabetes (n, %) 11 (27%) 10 (25%) 0.80
LVEF (%) (mean) 38 38
Hypertension (n, %) 14 (35%) 27 (67%) 0.004
CABG, coronary artery bypass graft; MI, myocardial infarction.
the ability independently to comprehend and complete the quality
of life questionnaires. Exclusion criteria were inability to consent,
awaiting heart transplantation, life expectancy of <1 year in the
opinion of the clinician, or a current device-related complication.
Cohort 1 was only observed, whereas Cohort 2 was used to
explore the utility of remote monitoring of implantable device
technologies in HF management, and staff workload issues. Patient
demographics are summarized in Table 1. Remote monitoring was
used as an ‘add on’ to usual care provided by the multidisciplinary
HF team. Of all patients approached, 83% consented to take part
in the feasibility study, and there were no drop-outs during the
6-month follow-up period.
The 40 patients in Cohort 2 (remote care pathway) were
randomized 1:1 to either daily or weekly monitoring for 3 months,
with all patients monitored weekly for the final 3 months of the
study. In the event of data from the implantable device suggesting
a need for a change in patient management, the patient and
the responsible primary care practitioner were telephoned. If
subsequent data indicated a poor response to the suggested
change in management, the patient was then invited to the hospital
clinic for a face-to-face review. Remote data downloads were
reviewed for both device functionality and disease state [arrhythmia
burden, non-sustained ventricular tachycardia (VT), sustained VT
requiring therapy, AF episodes, heart rate variability, activity data,
and thoracic impedance data]. ‘Alert’ facilities capable of signalling
potential deterioration in patient clinical status or the device
system were programmed ‘on’ but could be switched off according
to the clinical judgement of the cardiologist with responsibility for
the patient. If an alert was triggered, the patient could hear the
audible alarm and then contacted the study monitor and performed
a remote data download; the monitor informed the responsible
attending senior clinician of the data transmission and he or she
then determined the appropriate clinical action.
In the event of clinical deterioration (but not severe enough
to necessitate emergency admission), patients contacted the ..
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.. monitor and performed a data download. The monitor then
gave the patient a management plan in the light of the available
information, with appropriate support from the primary care team
to ensure implementation within one working day. In the event
of an emergency, the patient accessed emergency services in the
usual way.
All healthcare contact was entered in a study-specific diary
by the patients. Monitoring staff and the patient’s cardiologist
recorded all study-related activity in the patient’s electronic
health record. In addition, all patients completed a generic
health-related quality of life questionnaire (SF-36, short version)
and a disease-specific questionnaire (Minnesota Living with Heart
Failure questionnaire) at enrolment and 6 months.
With 83% of patients approached regarding the feasibility study
consenting to take part, and with no drop-outs at 6 months,
we considered a larger adequately powered study to assess
clinical and cost-effectiveness. It was also clear that one remote
monitor could handle the work related to monitoring of 200
patients within a standard working week. The approach used
in the feasibility study was used in the design process for the
main study, the development of the procedures handbook, and
the data collection system. It was critical to developing the role
of the remote monitoring staff in guiding patient care in the
community.
REmote Monitoring: an evaluation
of implantable devices for management
of Heart Failure patients
Study design
REM-HF is a multicentre, randomized, non-blinded, parallel group
study. The trial is registered with the National Institute of Health
Research in the UK (Trial no. 10383). Patients are randomized in
a 1:1 ratio to optimal medical management (usual care) or optimal
medical management informed by weekly remote monitoring of
the data from their implanted device. The study is event driven,
with a sample size of 1650 patients [Thus P = 0.05 and power
>90% with a maximum hazard ratio (HR) of 0.755 and maximum
of 5% withdrawals]. The first patient was randomized in September
2011 and the study is expected to finish in early 2016. The average
follow-up time will depend on the speed of patient recruitment
and the event rate, but is anticipated to be ∼32 months. Minimum
follow-up will be 24 months, and maximum ∼42 months.
Objectives
The primary study endpoint is the survival time to first event of
all-cause death or unplanned hospitalization for cardiovascular
reasons (at maximum HR 0.755), as assessed by the Endpoint
Review Committee (Appendix 1) using data from primary
and secondary care records, coroner reports, and the death
certificate.
Secondary endpoints are combined cardiovascular mortal-
ity and cardiovascular hospitalization, HF hospitalization, and
cost-effectiveness. The main outcome measure in the economic
© 2014 The Authors
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evaluation will be cost per QALY, with quality of life assessed using
the EuroQol (EQ5D), Short-Form 12 (SF-12), and Kansas City
Cardiomyopathy Questionnaire (KCCQ). Costs will be measured
using an NHS perspective. As part of the study, we will record the
costs associated with providing remote monitoring, as well as any
routine cardiac care received in each group. Resource use will be
obtained from a variety of sources as appropriate, including hospi-
tal records and directly from participants. We will follow National
Institute for Health and Care Excellence (NICE) guidelines
(Modified Client Services Inventory) for economic evaluation.
Patients
The intended study population for this study is patients with HF
and an implanted cardiac device (ICD, CRT-D, or CRT-P) that can
be monitored remotely. Eligible subjects meeting the inclusion and
exclusion criteria (detailed below) at nine English hospitals will be
considered for the study.
Inclusion criteria
Participants will all have received an implantable device at least 6
months previously (to allow for system stabilization) that is set-up .
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.. for the treatment and monitoring of chronic HF. Patients receiving
these devices will be doing so according to clinical requirement
and UK guidance from NICE, and not for the purposes of this
study. All patients will have symptomatic HF (NYHA class II–IV)
documented at the time of study enrolment. In addition, recruited
patients will have been on stable medical therapy for HF for at
least 6 weeks prior to recruitment, have the ability independently
to comprehend and complete the study health-related quality of
life questionnaires, have the ability to give informed consent, be
on optimal medical therapy according to the treating physician
and the applicable professional guidelines (NICE), and have had
their device programmed to give optimal therapy according to the
treating physician.
Exclusion criteria
Participants will be excluded from the study if they are unable to
use the remote monitoring download technology due to mental or
physical limitations, are less than 18 years old, pregnant, awaiting
heart transplantation or have a life expectancy of <1 year due to
non-cardiovascular disease in the opinion of the treating physician,
have current device-related complications, device change, or lead
replacements within 30 days, or acute myocardial infarction or
Figure 1 Study Flowchart
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coronary intervention/coronary artery bypass grafting within 3
months.
Patient randomization
This will be performed centrally via a study-specific electronic case
report form management system, using a randomization schedule
that is stratified by recruiting site, with randomly permuted blocks
of four and six patients.
Study plan
The study schedule is shown in Figure 1. All patients will be
followed-up for a minimum of 24 months.
Intervention
Remote care pathway
The remote-monitoring informed care pathway was developed
from our experience in the feasibility study, informed also by litera-
ture and guideline review.1 The REM-HF steering group (Appendix
1) agreed the operational procedures which governed the actions
of remote monitors in response to data. A formalized ‘Procedural
Handbook’ comprehensively dealt with HF, arrhythmia, and device
management, indicating what changes would be likely to be neces-
sary in response to changes in remotely collected data. The site
remote monitor was responsible for co-ordinating such changes,
with physician support as necessary, using telephone, primary care,
or direct patient review in secondary/tertiary care.
Usual care pathway
Usual care pathways will differ somewhat between centres,
although all operate under NICE recommendations. Remote
device follow-up for technical checks is currently performed, usu-
ally 3 or 6 monthly, in all centres. This ‘usual’ device care will be
unaffected as the study assesses the value of weekly pre-emptive
monitoring of disease state and not routine device technical
follow-up.
Quality of life assessment
All participants will complete the health-related quality of life
questionnaires SF-12, EQ5D, and the KCCQ at enrolment, at 3,
6, 12, and 24 months, and at the end of the study. The initial
quality of life questionnaires will be completed at the time of
patient enrolment in the hospital. Subsequent assessments will
be performed by the patients in their homes. The forms will be
sent to them by post with a pre-paid return-addressed envelope
to facilitate the return of completed forms. Receipt of the forms
and their return will be managed by the study administration
staff.
Interim analyses
An Independent Data and Safety Monitoring Committee will review
recruitment, data completeness, and endpoints, and ensure no ..
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.. adverse effects from remote monitoring, at appropriate time points
during the study. There will be one interim analysis at 400 primary
endpoints.
Statistical considerations
The primary analysis will be performed on adjudicated endpoints
in the intention-to-treat population (all randomized patients), fol-
lowing a group sequential design. The interim analysis and the final
analysis will consist of a two-sided log-rank test comparing the con-
trol and intervention groups.
The null hypothesis is that the time to first event in the
intervention group is identical to the time to first event in the
control group. The alternative hypothesis is that the time to
first event in the intervention group is different from the time
to first event in the control group. To maintain study blinding,
the statistician of the Data and Safety Monitoring Committee
will link the time to event data at the interim analysis to the
randomization code, calculate the log-rank statistic, and compare
it with pre-defined limits. Kaplan–Meier curves will be used to
visualize survival data.
Secondary analyses
Secondary endpoints will be analysed according to the type of
scale. Time-to-event endpoints will be analysed in the same ways
as the primary endpoint; dichotomous variables will be analysed
by a likelihood 𝜒2 test; continuous endpoints will be analysed by
analysis of covariance, including the baseline value as a covariate if
available; variables with a right-skewed distribution within random
groups will be log-transformed prior to analysis. All secondary
endpoint comparisons will be performed at 𝛼 = 0.05, without
adjustment for multiplicity. Extended analyses will be conducted
using regression models (linear, logistic, or Cox proportional
hazards) to explore further the influence of patient characteristics
and clinical conditions on outcome. The list of such variables
includes age, gender, site, co-morbidities, type of device, NYHA
class, ischaemic/non-ischaemic HF, and underlying cardiac rhythm
(AF vs. sinus rhythm).
Sample size
The study is designed to demonstrate a 20% reduction in the pri-
mary endpoint with an overall type 1 error rate of 5% (two-sided)
including one interim analysis, and with a power of 90%. Based on
data from COMPANION23 and CARE-HF24 trials, with a patient
population comparable with that of this study, we conservatively
assume an event rate of 40% at 24 months. Accordingly, a mini-
mum of 546 events will be observed if the study is not stopped at
the interim analysis. To reach that goal, a range of possible recruit-
ment and follow-up scenarios have been considered. We have now
recruited 1650 patients over an 18-month period, who will have
minimum of 24 months follow-up, allowing for a 5% drop-out rate,
and the use of multifactorial rather than unifactorial modelling. We
are confident that the expected drop-out rate is a realistic estimate
from our feasibility analysis.
© 2014 The Authors
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Ethics and monitoring
The Steering Committee is responsible for the clinical and scien-
tific conduct of the study and the publication of the results. An
independent Endpoint Review Committee reviews and adjudicates
all pre-specified events according to established definitions. Both
committees only have access to blinded data while the study is
underway. An independent Supervisory Committee oversees the
study and an independent Data and Safety Monitoring Commit-
tee reviews the interim analysis. Members of the committees are
listed in Appendix 1. The trial design was approved by the relevant
Research Ethics Committee. The trial is being conducted in accor-
dance with UK laws, Good Clinical Practice, and the Declaration
of Helsinki 2002.
Discussion
The ready availability of remote monitoring technologies in many
HF patients in developed countries raises the possibility of improv-
ing outcome and reducing healthcare costs. However, the evi-
dence base for the benefits (and disadvantages) of adopting such
an approach is weak. Frequent pre-emptive remote monitoring by
implantable devices may enable early identification and treatment
of pulmonary congestion and malignant arrhythmias (the two main
mechanisms for mortality in HF), which could reduce HF morbidity
and related hospitalization.25
The care model and technologies used in this trial will offer per-
sonalized healthcare through remote patient management in the
community, using secondary and tertiary care expertise and inter-
ventions as required. Our pilot study showed that remote moni-
toring is readily accepted (and continued) by patients who have an
implantable cardiac electronic device. Weekly remote monitoring
is feasible for healthcare professionals trained to undertake such
a task, and we wish to test the clinical and cost-effectiveness of
this approach when applied to a large number of individuals at nine
English hospitals, with varying types of clinical service.
Redesigning care pathways to incorporate remote monitoring is
not straightforward, and before doing so the clinical community
wishes to see robust clinical effectiveness evidence from large ran-
domized trials.We believe that REM-HF will provide such evidence,
and that its cost-effectiveness data will inform new reimbursement
models that are essential for the optimal deployment of monitoring
technologies in an increasingly challenged healthcare environment.
Conclusions
REM-HF is an important randomized controlled trial that will
assess whether weekly remote monitoring of data collected from
implantable cardiac electronic devices in patients can reduce mor-
tality and morbidity in patients with chronic HF, compared with
usual care. In addition, it will provide an assessment of the value
for money of this approach. The results of the REM-HF study will
provide further clarification of the benefits of remote monitoring
in patients with HF, and may have important implications for the
individualized therapeutic strategies targeted at reducing the risk ..
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.. and consequences of arrhythmia and decompensation for those liv-
ing with the syndrome, and the way we organize HF care within the
healthcare systems.
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